Leo Wealth LLC bought a new position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 150,478 shares of the company's stock, valued at approximately $3,240,000.
A number of other institutional investors and hedge funds also recently made changes to their positions in KVUE. Clearstead Advisors LLC acquired a new position in shares of Kenvue during the third quarter worth about $25,000. Planned Solutions Inc. acquired a new stake in Kenvue during the fourth quarter worth approximately $27,000. Pacific Capital Wealth Advisors Inc. acquired a new stake in Kenvue during the fourth quarter worth approximately $28,000. CVA Family Office LLC acquired a new stake in Kenvue during the fourth quarter worth approximately $32,000. Finally, Pinnacle Bancorp Inc. grew its position in Kenvue by 51.3% during the fourth quarter. Pinnacle Bancorp Inc. now owns 1,552 shares of the company's stock worth $33,000 after buying an additional 526 shares in the last quarter. Institutional investors own 97.64% of the company's stock.
Kenvue Stock Up 4.0 %
Shares of KVUE traded up $0.71 during trading hours on Monday, hitting $18.79. The stock had a trading volume of 20,146,425 shares, compared to its average volume of 18,907,533. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.99 and a quick ratio of 0.68. The firm has a 50 day simple moving average of $19.37 and a 200-day simple moving average of $20.09. The firm has a market capitalization of $35.97 billion and a P/E ratio of 24.08. Kenvue Inc. has a 1-year low of $17.75 and a 1-year high of $26.74.
Kenvue (NYSE:KVUE - Get Free Report) last issued its earnings results on Tuesday, May 7th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.25 by $0.03. The company had revenue of $2.89 billion during the quarter, compared to the consensus estimate of $3.79 billion. Kenvue had a return on equity of 21.06% and a net margin of 9.63%. Kenvue's quarterly revenue was down 24.9% on a year-over-year basis. Sell-side analysts predict that Kenvue Inc. will post 1.18 EPS for the current fiscal year.
Kenvue Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Wednesday, May 22nd. Shareholders of record on Wednesday, May 8th were given a dividend of $0.20 per share. The ex-dividend date of this dividend was Tuesday, May 7th. This represents a $0.80 annualized dividend and a dividend yield of 4.26%. Kenvue's dividend payout ratio is currently 102.56%.
Wall Street Analyst Weigh In
A number of research analysts have recently commented on the company. HSBC increased their price target on Kenvue from $20.00 to $21.00 and gave the company a "hold" rating in a research note on Wednesday, May 8th. Citigroup reaffirmed a "neutral" rating and set a $21.00 target price on shares of Kenvue in a research report on Tuesday, May 28th. The Goldman Sachs Group began coverage on Kenvue in a research report on Friday, March 1st. They set a "neutral" rating and a $20.00 target price for the company. Sanford C. Bernstein started coverage on Kenvue in a research report on Thursday, April 11th. They set an "underperform" rating and a $18.00 target price for the company. Finally, William Blair started coverage on Kenvue in a research report on Wednesday, April 3rd. They issued a "market perform" rating for the company. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $23.09.
Read Our Latest Analysis on KVUE
About Kenvue
(Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
See Also
- Five stocks we like better than Kenvue
- Buffett Bails on BYD: What It Means forthe Future of EV Stocks
- How Investors Can Find the Best Cheap Dividend Stocks
- Domino’s vs. Papa John's: Stock Showdown of Pizza Giants
- Using the MarketBeat Stock Split Calculator
- Williams-Sonoma Makes Stock More Accessible with a Stock Split
→ Protect Your Bank Account from China (From Behind the Markets) (Ad)
Should you invest $1,000 in Kenvue right now?
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
7 Stocks to Own Before the 2024 Election
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
